Collaborating with AEBi
The sole external requirement in the screening process is a defined target - usually an illness-related protein.
The great advantage of our platform is that it generates very specific and effective leads to any protein or part of a protein as a target. What we need is a verified defined target (illness-related protein)
-
We will use our technology to isolate a therapeutic peptide.
-
One of the great advantages of our technology is the relative speed and the built-in success of the process.
-
It will take us about 6 months to get results (functional peptides, which will comprise the drug).
-
Usually we are also able to milestone the intermediate results to make sure that we are on the correct path.
“About 70% of the industry’s new sales today come from drugs originated in small companies, up from 30% in 1990, according to the Boston Consulting Group. And new-drug approvals are up from the low levels of just a few years ago.”
“A study by Bain & Company found that the pharmaceutical companies delivering the most shareholder return made strategic acquisitions to supplement their own declining research and development budgets (R&D).”
“The major pharmaceutical companies seeking to acquire novel technologies or new drugs from young biopharmaceuticals may opt for partnering with biopharmaceuticals rather than acquiring them”.
